Masimo (NASDAQ:MASI) Sets New 12-Month High at $152.20
Masimo Co. (NASDAQ:MASI)’s stock price reached a new 52-week high on Thursday . The company traded as high as $152.20 and last traded at $151.75, with a volume of 12860 shares. The stock had previously closed at $149.68.
A number of equities analysts recently weighed in on MASI shares. Stifel Nicolaus increased their price objective on shares of Masimo from $150.00 to $160.00 and gave the stock a “buy” rating in a research report on Friday, May 17th. UBS Group reaffirmed a “buy” rating and set a $25.00 price objective on shares of Infineon Technologies in a research report on Tuesday, May 7th. Piper Jaffray Companies raised their price target on shares of Adverum Biotechnologies from $8.00 to $12.00 and gave the company an “overweight” rating in a research report on Friday, May 17th. Needham & Company LLC reissued a “hold” rating on shares of KLA-Tencor in a research report on Tuesday, May 7th. Finally, BTIG Research cut shares of Masimo from a “buy” rating to a “neutral” rating and set a $134.50 price target for the company. in a research report on Tuesday, April 16th. One analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. Masimo has an average rating of “Buy” and an average price target of $154.25.
The firm has a market capitalization of $8.00 billion, a P/E ratio of 50.38, a PEG ratio of 2.99 and a beta of 1.14. The business’s 50-day moving average is $142.62.
In other news, CEO Joe E. Kiani sold 100,000 shares of Masimo stock in a transaction on Monday, July 1st. The shares were sold at an average price of $150.14, for a total transaction of $15,014,000.00. Following the completion of the sale, the chief executive officer now directly owns 239,241 shares of the company’s stock, valued at approximately $35,919,643.74. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Anand Sampath sold 30,000 shares of Masimo stock in a transaction on Friday, June 14th. The stock was sold at an average price of $142.39, for a total transaction of $4,271,700.00. Following the sale, the executive vice president now directly owns 27,518 shares of the company’s stock, valued at $3,918,288.02. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 186,242 shares of company stock valued at $27,360,053. Corporate insiders own 11.50% of the company’s stock.
Several institutional investors have recently added to or reduced their stakes in MASI. Claybrook Capital LLC purchased a new stake in shares of Masimo during the 4th quarter worth $25,000. West Oak Capital LLC purchased a new stake in shares of Masimo during the 1st quarter worth $28,000. FinTrust Capital Advisors LLC purchased a new stake in shares of Masimo during the 1st quarter worth $61,000. Valeo Financial Advisors LLC purchased a new stake in shares of Masimo during the 1st quarter worth $69,000. Finally, Penserra Capital Management LLC purchased a new stake in shares of Masimo during the 1st quarter worth $92,000. 83.03% of the stock is owned by institutional investors and hedge funds.
Masimo Company Profile (NASDAQ:MASI)
Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.
See Also: What are gap-up stocks?
Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.